Genetic and epigenetic characterization of chronic lymphocytic leukemia with chromosomal translocations leading to enhancer hijacking by oncogenes
Year: 2026
Type: dissertation
Study design: Observational Study
Abstract: Chromosomal translocations lead to the rearrangement of segments of two chromosomes. They can occur in the germline and in somatic tissues. Translocations in somatic tissues can drive various neoplasms, e.g. hematological malignancies. These translocations can lead to the disruption of target genes, formation of fusion genes or enhancer hijacking. Chronic lymphocytic leukemia (CLL) is characterized by a clonal accumulation of lymphocytes. Chromosomal translocations in this B-cell lymphoma mainly involve immunoglobulin loci (IG). BCL3 is an oncogene targeted in CLL by IG-translocations functioning through enhancer hijacking. Yet many other IG-translocation partners in CLL remain unidentified. Non-IG-translocations are less frequent in CLL but have been documented. Therefore, this thesis addresses three aims: (1) characterizing the genetic and epigenetic landscape of IGH::BCL3-translocated B-cell neoplasms, (2) identifying novel IG-translocation partners in CLL and (3) characterizing the recurrent chromosomal translocation t(1;6)(p35.3;p25.2) in CLL. To reach these aims, 238 B-cell neoplasms, primarily CLL (n=234), and publicly available control datasets were included. Breakpoints in 232 samples and recurrent imbalances in 225 samples were identified by FISH. Breakpoint junctions were identified using tNGS (n=20) and WGS (n=67) and verified by Sanger sequencing (n=39). Somatic alterations were detected using custom panel sequencing (n=214). The IGHV mutational status (n=230) and its stereotype subsets (n=189) were determined. RNA expression was assessed using the HTG mRNA pan B-cell panel (n=6), qPCR (n=27) or RNA sequencing (n=3). Protein expression was detected by Western Blot (n=9). Analysis of DNA methylation was conducted using EPIC BeadChip array data (n=85). The aim of the first part was to characterize 84 B-cell neoplasms positive for IGH::BCL3-translocation with focus on breakpoint mapping, additional genetic alterations and DNA methylation profiling. In 27 patients, examination of breakpoint junctions revealed chromosomal breaks upstream of BCL3 in CLL in 25 patients. Aberrant class-switch recombination (CSR) in 26 of 27 patients was the main cause for the translocation. The predominant target was IGHA in 41% (11/27) of patients. An unmutated IGHV was exhibited in 95% (78/82) of patients, with a predominance of CLL stereotype subset #8 (17%, 11/64). Common genetic abnormalities included trisomy 12 in 61% (51/83) of CLL. Frequent mutations were identified in NOTCH1 (32%, 25/79), BRAF (14%, 11/79), and FBXW7 (14%, 11/79). Epigenetic profiling classified 77% (51/66) of IGH::BCL3-translocated cases as naïve B-cell-like subtype with 1063/1985 differentially methylated CpGs resembling the DNA methylation pattern of plasma cell features. Clinically, these patients showed shorter PFS and OS with chemoimmunotherapy, but not with venetoclax. Taken together, this suggests that CLL cases with IGH::BCL3-translocation form a biologically uniform subgroup within the CLL spectrum. In the second part, the aim was to identify novel translocation partners and characterize the genetic landscape of IG-translocated CLL. The cohort included 144 patients with IG-translocated CLL with partner genes other than BCL2, CCND1, BCL3, and MYC. 25 distinct IG-translocation partners were identified. Breakpoint analysis indicated that 78% (32/41) of cases involved aberrant CSR. The IGHV status was unmutated in 74% (107/144) of cases. The most frequent translocation, IGH::BCL11A (12/144), consistently led to elevated expression of the BCL11A-S protein isoform. In three cases, an IGH::NKX2.6-translocation was caused by illegitimate VDJ recombination with unmutated IGHV and significant NKX2.6 overexpression. Another recurrently identified partner gene is METRNL, detected in four cases. This study identified known and previously unreported IG-translocations in CLL. It refines the concept of cell of origin in CLL by suggesting that IGH::NKX2.6-translocated CLL may arise from an earlier B-cell stage. The aim of the third part addressed the characterization of ten cases with the chromosomal translocation t(1;6)(p35.3;p25.2) in CLL. The translocation involves IRF4 on 6p25 and RCC1 on 1p35. Translocation breakpoints were located in the 5′UTR of both genes. This results in RCC1::IRF4 fusion transcripts that preserve the protein-coding regions and protein expression levels of RCC1 and IRF4. The dissertation successfully achieves all three aims by highlighting the importance of identifying translocations in CLL. Translocation subgroups in CLL may arise from different B-cell developmental stages and show, in case of IGH::BCL3, a favorable response to venetoclax. The favorable response and the role of BCL3 in NFκB signaling may suggest that NFκB inhibitors require investigation in clinical trials for this CLL subgroup. These findings demonstrate that detailed molecular profiling including translocation analysis is essential to improve diagnosis and treatment strategies in CLL.
DOI: 10.18725/oparu-61428
Author: Drewes, Cosima
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7222920389
